Monoacylglycerol O-acyltransferase 1 is regulated by peroxisome proliferator-activated receptor γ in human hepatocytes and increases lipid accumulation

被引:14
作者
Yu, Jung Hwan [1 ,2 ]
Lee, Yoo Jeong [3 ]
Kim, Hyo Jung [1 ]
Choi, Hyeonjin [1 ]
Choi, Yoonjeong [1 ,2 ]
Seok, Jo Woon [1 ,2 ]
Kim, Jae-Woo [1 ,2 ,4 ]
机构
[1] Yonsei Univ, Dept Biochem & Mol Biol, Inst Genet Sci, Integrated Genom Res Ctr Metab Regulat,Coll Med, Seoul 120752, South Korea
[2] Yonsei Univ, Brain Korea PLUS Project Med Sci 21, Seoul 120752, South Korea
[3] Natl Inst Hlth, Ctr Biomed Sci, Div Metab Dis, Cheongwon Gun 363951, Chungbuk, South Korea
[4] Yonsei Univ, Severance Biomed Sci Inst, Coll Med, Seoul 120752, South Korea
基金
新加坡国家研究基金会;
关键词
MGAT1; PPAR gamma; Hepatic steatosis; Primary hepatocytes; Promoter; NONALCOHOLIC FATTY LIVER; PPAR-GAMMA; INSULIN-RESISTANCE; HEPATIC STEATOSIS; MOUSE MODEL; EXPRESSION; OBESITY; STEATOHEPATITIS; IDENTIFICATION; LIPOGENESIS;
D O I
10.1016/j.bbrc.2015.03.095
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Monoacylglycerol O-acyltransferase (MGAT) is an enzyme that is involved in triglyceride synthesis by catalyzing the formation of diacylglycerol from monoacylglycerol and fatty acyl CoAs. Recently, we reported that MGAT1 has a critical role in hepatic TG accumulation and that its suppression ameliorates hepatic steatosis in a mouse model. However, the function of MGAT enzymes in hepatic lipid accumulation has not been investigated in humans. Unlike in rodents, MGAT3 as well as MGAT1 and MGAT2 are present in humans. In this study, we evaluated the differences between MGAT subtypes and their association with peroxisome proliferator-activated receptor gamma (PPAR gamma), a regulator of mouse MGAT1 expression. In human primary hepatocytes, basal expression of MGATI was lower than that of MGAT2 or MGAT3, but was strongly induced by PPAR gamma overexpression. A luciferase assay as well as an electro-mobility shift assay revealed that human MGATI promoter activity is driven by PPAR gamma by direct binding to at least two regions of the promoter in 2931 and HepG2 cells. Moreover, siRNA-mediated suppression of MGAT1 expression significantly attenuated lipid accumulation by PPAR gamma overexpression in HepG2 cells, as evidenced by oil-red-O staining. These results suggest that human MGAT1 has an important role in fatty liver formation as a target gene of PPAR gamma, and blocking MGAT1 activity could be an efficient therapeutic way to reduce nonalcoholic fatty liver diseases in humans. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:715 / 720
页数:6
相关论文
共 30 条
  • [1] Abdeen Mohammad Bosem, 2006, J Cardiometab Syndr, V1, P36, DOI 10.1111/j.0197-3118.2006.05523.x
  • [2] Nonalcoholic fatty liver disease
    Brunt, Elizabeth M.
    Wong, Vincent W. -S.
    Nobili, Valerio
    Day, Christopher P.
    Sookoian, Silvia
    Maher, Jacquelyn J.
    Bugianesi, Elisabetta
    Sirlin, Claude B.
    Neuschwander-Tetri, BrentA.
    Rinella, Mary E.
    [J]. NATURE REVIEWS DISEASE PRIMERS, 2015, 1
  • [3] The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans
    Benhamed, Fadila
    Denechaud, Pierre-Damien
    Lemoine, Maud
    Robichon, Celine
    Moldes, Marthe
    Bertrand-Michel, Justine
    Ratziu, Vlad
    Serfaty, Lawrence
    Housset, Chantal
    Capeau, Jacqueline
    Girard, Jean
    Guillou, Herve
    Postic, Catherine
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2012, 122 (06) : 2176 - 2194
  • [4] Catalytic properties of MGAT3, a putative triacylgycerol synthase
    Cao, Jingsong
    Cheng, Long
    Shi, Yuguang
    [J]. JOURNAL OF LIPID RESEARCH, 2007, 48 (03) : 583 - 591
  • [5] Identification of acyl coenzyme A:Monoacylglycerol acyltransferase 3, an intestinal specific enzyme implicated in dietary fat absorption
    Cheng, D
    Nelson, TC
    Chen, J
    Walker, SG
    Wardwell-Swanson, J
    Meegalla, R
    Taub, R
    Billheimer, JT
    Ramaker, M
    Feder, JN
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (16) : 13611 - 13614
  • [6] PPARs and the complex journey to obesity
    Evans, RM
    Barish, GD
    Wang, YX
    [J]. NATURE MEDICINE, 2004, 10 (04) : 355 - 361
  • [7] Obesity and Nonalcoholic Fatty Liver Disease: Biochemical, Metabolic, and Clinical Implications
    Fabbrini, Elisa
    Sullivan, Shelby
    Klein, Samuel
    [J]. HEPATOLOGY, 2010, 51 (02) : 679 - 689
  • [8] Abrogating Monoacylglycerol Acyltransferase Activity in Liver Improves Glucose Tolerance and Hepatic Insulin Signaling in Obese Mice
    Hall, Angela M.
    Soufi, Nisreen
    Chambers, Kari T.
    Chen, Zhouji
    Schweitzer, George G.
    McCommis, Kyle S.
    Erion, Derek M.
    Graham, Mark J.
    Su, Xiong
    Finck, Brian N.
    [J]. DIABETES, 2014, 63 (07) : 2284 - 2296
  • [9] Evidence for regulated monoacylglycerol acyltransferase expression and activity in human liver
    Hall, Angela M.
    Kou, Kou
    Chen, Zhouji
    Pietka, Terri A.
    Kumar, Mrudula
    Korenblat, Kevin M.
    Lee, Kyuha
    Ahn, Kay
    Fabbrini, Elisa
    Klein, Samuel
    Goodwin, Bryan
    Finck, Brian N.
    [J]. JOURNAL OF LIPID RESEARCH, 2012, 53 (05) : 990 - 999
  • [10] Regulation of Steatohepatitis and PPARγ Signaling by Distinct AP-1 Dimers
    Hasenfuss, Sebastian C.
    Bakiri, Latifa
    Thomsen, Martin K.
    Williams, Evan G.
    Auwerx, Johan
    Wagner, Erwin F.
    [J]. CELL METABOLISM, 2014, 19 (01) : 84 - 95